Novo Nordisk A/S (NVO)
124.76
-1.40
(-1.11%)
USD |
NYSE |
Apr 25, 10:14
Novo Nordisk Enterprise Value: 561.51B for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 561.51B |
| April 23, 2024 | 572.58B |
| April 22, 2024 | 557.50B |
| April 19, 2024 | 546.12B |
| April 18, 2024 | 546.32B |
| April 17, 2024 | 554.27B |
| April 16, 2024 | 549.45B |
| April 15, 2024 | 551.46B |
| April 12, 2024 | 554.18B |
| April 11, 2024 | 558.17B |
| April 10, 2024 | 556.08B |
| April 09, 2024 | 555.76B |
| April 08, 2024 | 567.36B |
| April 05, 2024 | 560.23B |
| April 04, 2024 | 551.77B |
| April 03, 2024 | 565.29B |
| April 02, 2024 | 562.92B |
| April 01, 2024 | 567.79B |
| March 28, 2024 | 571.58B |
| March 27, 2024 | 570.02B |
| March 26, 2024 | 576.10B |
| March 25, 2024 | 574.50B |
| March 22, 2024 | 573.20B |
| March 21, 2024 | 578.00B |
| March 20, 2024 | 580.37B |
| Date | Value |
|---|---|
| March 19, 2024 | 584.87B |
| March 18, 2024 | 591.66B |
| March 15, 2024 | 589.34B |
| March 14, 2024 | 599.22B |
| March 13, 2024 | 594.36B |
| March 12, 2024 | 601.59B |
| March 11, 2024 | 584.32B |
| March 08, 2024 | 592.49B |
| March 07, 2024 | 605.23B |
| March 06, 2024 | 555.38B |
| March 05, 2024 | 554.94B |
| March 04, 2024 | 569.67B |
| March 01, 2024 | 553.06B |
| February 29, 2024 | 533.21B |
| February 28, 2024 | 541.11B |
| February 27, 2024 | 544.19B |
| February 26, 2024 | 549.82B |
| February 23, 2024 | 549.64B |
| February 22, 2024 | 554.41B |
| February 21, 2024 | 538.39B |
| February 20, 2024 | 540.71B |
| February 16, 2024 | 552.14B |
| February 15, 2024 | 542.08B |
| February 14, 2024 | 548.95B |
| February 13, 2024 | 534.22B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
110.49B
Minimum
May 16 2019
605.23B
Maximum
Mar 07 2024
245.78B
Average
228.77B
Median
Aug 11 2021
Enterprise Value Benchmarks
| Amgen Inc | 199.98B |
| AstraZeneca PLC | 242.40B |
| Sanofi SA | 124.93B |
| Viking Therapeutics Inc | 6.177B |
| Evaxion Biotech AS | 24.60M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.170B |
| Revenue (Quarterly) | 9.505B |
| Total Expenses (Quarterly) | 5.643B |
| EPS Diluted (Quarterly) | 0.7086 |
| Gross Profit Margin (Quarterly) | 84.80% |
| Profit Margin (Quarterly) | 33.35% |
| Earnings Yield | 2.17% |
| Operating Earnings Yield | 2.66% |
| Normalized Earnings Yield | 2.166 |